Guardant Health (GH) reported $281.27 million in revenue for the quarter ended December 2025, representing a year-over-year increase of 39.4%. EPS of -$0.50 for the same period compares to -$0.62 a year ago.The reported revenue represents a surprise of +0.47% over the Zacks Consensus Estimate of $279.96 million. With the consensus EPS estimate being -$0.42, the EPS surprise was -18.12%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to ...

Core Insights - Labcorp reported a strong performance in 2025 with over 7% revenue growth, 13% adjusted EPS growth, and margin expansion of more than 50 basis points [3][5] - The company highlighted a robust pipeline for mergers and acquisitions (M&A) and a backlog of $8.7 billion in Biopharma Laboratory Services (BLS) [4][11] Financial Performance - Fourth-quarter revenue reached $3.5 billion, up 5.6% year over year, driven by organic growth of 3.8%, acquisitions contributing 1.2%, and foreign currency translation of 0.6% [8] - Adjusted EPS for the fourth quarter was $4.07, reflecting an 18% increase year over year [9] - Free cash flow for the quarter was $490 million, down from $665 million, primarily due to working capital timing [9] Growth Strategy - The company launched over 130 new tests in 2025, focusing on oncology, women's health, neurology, and autoimmune diseases [6][7] - Labcorp's OnDemand service expanded to offer tests for over 200 biomarkers, including food allergies and thyroid health [7] - Management emphasized technology and AI initiatives to enhance efficiency and customer experience, including AI-driven tools for scheduling and reporting [7] M&A Activity - In the fourth quarter, Labcorp completed several acquisitions, including outreach laboratory services from Parkview Health and anatomic pathology assets from Incyte Diagnostics [2] - The company signed or closed 13 deals, contributing over $1 billion in revenue growth over the past three years [2] 2026 Guidance - Labcorp forecasts enterprise revenue growth of 4.7% to 6% for 2026, with adjusted EPS expected to be between $17.65 and $18.25, implying about 9% growth at the midpoint [5][15] - Diagnostics revenue is projected to rise 5% to 6%, with half of the growth expected from volume and half from price/mix [13] - BLS revenue is anticipated to grow 3% to 5%, with Central Labs expected to grow mid-single digits organically [14] Operational Highlights - Diagnostics revenue was $2.7 billion, up 5.5%, with organic growth of 4.1% and acquisitions contributing 1.5% [10] - BLS revenue was $793 million, up 3.4%, with Central Labs revenue growing 11.1% [11] - The company reported a book-to-bill ratio of 1.16 for the quarter, indicating strong demand in Central Labs [12] Leadership Changes - Labcorp announced the upcoming retirement of key executives, with successors appointed under a succession plan [21]

Core Insights - Guardant Health reported a breakout year in 2025, with total revenue growth accelerating to 33% year-over-year, driven by innovation in its Smart Platform and strong commercial execution [2][5] - The company highlighted the success of its Shield product in the blood-based colorectal cancer screening market, with nearly 100,000 patients screened since FDA approval [2][5] - Guardant Health plans to launch multiple groundbreaking products in 2026 to sustain growth momentum in its Oncology business [2] Financial Performance - For Q4 2025, total revenue was approximately $280 million, an increase of 39% compared to Q4 2024 [5] - The company reported approximately 79,000 oncology tests in Q4 2025, a 38% increase year-over-year [5] - For the full year 2025, total revenue reached approximately $981 million, reflecting a 33% increase from 2024 [5] - The number of oncology tests conducted in 2025 was approximately 276,000, marking a 34% increase [5] - Shield screening tests totaled approximately 87,000 in 2025, up from 6,400 in the prior year [5] Cash Flow and Financial Position - Preliminary unaudited free cash flow was approximately negative $54 million for Q4 2025 and approximately negative $233 million for the full year 2025 [2] - As of December 31, 2025, the company had approximately $1.3 billion in cash, cash equivalents, restricted cash, and marketable debt securities [2]

Core Insights - Guardant Health reported a revenue of $265.2 million for the quarter ended September 2025, reflecting a year-over-year increase of 38.5% [1] - The earnings per share (EPS) was -$0.39, an improvement from -$0.45 in the same quarter last year, with an EPS surprise of +18.75% compared to the consensus estimate of -$0.48 [1] - The revenue exceeded the Zacks Consensus Estimate of $234.58 million by 13.05% [1] Financial Performance Metrics - Total oncology tests performed reached 74,000, surpassing the average estimate of 66,824 by three analysts [4] - Revenue from oncology was $184.4 million, exceeding the average estimate of $164.62 million from four analysts [4] - Revenue from biopharma and data was $54.73 million, compared to the average estimate of $48.38 million [4] - Revenue from screening was $24.11 million, significantly higher than the estimated $16.31 million [4] - Revenue from licensing and other sources was $1.95 million, slightly below the average estimate of $2.35 million [4] Stock Performance - Guardant Health's shares have returned +11.4% over the past month, outperforming the Zacks S&P 500 composite's +3.8% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]